Characterizing Rheumatoid Arthritis With 68Ga-FAPI PET/CT
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is
overexpressed in cancer-associated fibroblasts and some inflammation, such as IgG4-related
disease and inflammatory bowel disease. Some researches identified FAP expression in synovial
samples taken from both rheumatoid arthritis and osteoarthritis patients.Thus this
prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for
diagnosis, therapy response assessment and follow-up of arthritis than 18F-FDG PET/CT.